Advertisement
NKTX vs RCKT
Which Stock Would AI Choose? Nkarta (NKTX) vs. Rocket Pharmaceuticals (RCKT) Stock Comparison
Key Takeaways
- Nkarta (NKTX) is a clinical-stage developer of engineered natural killer (NK) cell therapies, while Rocket Pharmaceuticals (RCKT) is a commercial-stage gene therapy company.
- RCKT has a regulatory approval (KRESLADI) and multiple late-stage catalysts, whereas NKTX remains pre-revenue with pivotal data expected later.
- Both companies hold substantial cash runways into the late 2020s, but RCKT recently diversified funding through a priority review voucher sale and a credit facility.
- The two names differ sharply on business maturity, pipeline focus, and risk profile, making their relative performance driven by distinct catalysts.
- Recent sentiment has favored RCKT on FDA alignment, while NKTX trades well below its cash position.
Introduction
Both NKTX and RCKT operate in biotechnology, yet they sit at very different points in the development lifecycle. This stock comparison examines two companies pursuing cutting-edge cell and gene therapies for serious diseases, making it relevant to investors who track clinical-stage catalysts, regulatory milestones, and relative performance within the small- and mid-cap biotech space. Understanding their market positioning, growth drivers, and risk factors can help traders evaluate where each name stands in the current market environment and how momentum, stability, and upcoming data readouts might shape the near-term outlook.
NKTX Overview and Recent Performance
NKTX is Nkarta, Inc., a clinical-stage biotechnology company developing allogeneic, "off-the-shelf" engineered natural killer (NK) cell therapies for autoimmune diseases. Its lead candidate, NKX019, is a CD19-targeted CAR-NK (chimeric antigen receptor natural killer) cell therapy being evaluated in the Ntrust-1 and Ntrust-2 trials across multiple autoimmune indications, including lupus nephritis and rheumatoid arthritis.
In recent weeks, the company has continued enrolling patients at the 4 billion cell dose level and began outpatient dosing through community-based sites following an agreement with the U.S. Food and Drug Administration (FDA). Management expects initial clinical data from Ntrust-1 and Ntrust-2 to be presented at a medical conference in 2026, a key catalyst. For its second quarter, Nkarta reported a net loss of roughly $40.4 million and held cash, cash equivalents, and investments of about $243.2 million, which it expects to fund operations into 2029. The stock has traded in a wide range over the past year, and its shares have remained well below historical highs, reflecting investor caution ahead of pivotal data.
RCKT Overview and Recent Performance
RCKT is Rocket Pharmaceuticals, Inc., a fully integrated, commercial-stage biotechnology company developing genetic medicines for rare diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. In March 2026, the FDA granted accelerated approval to KRESLADI, its gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), marking the company's first approved product.
Recent market activity has centered on the company's cardiovascular pipeline, led by RP-A501, an adeno-associated virus (AAV)-based gene therapy for Danon disease. Rocket announced alignment with the FDA on continued enrollment and dosing in the pivotal Phase 2 trial, with the first three patients treated under a modified protocol showing no significant safety concerns. The company also strengthened its balance sheet, selling a Rare Pediatric Disease Priority Review Voucher for $180 million and securing a credit facility of up to $150 million from Hercules Capital. As of June 30, 2026, Rocket held cash, cash equivalents, and investments of approximately $283.7 million. These catalysts have supported a relatively firmer share price trend in recent weeks.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's most promising automated trading strategies. Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance record, and statistics, as well as a distinct set of tickers it trades—ranging from high-frequency short-term approaches to longer-horizon trend-following models. This variety allows traders to explore automated tools aligned with their own risk tolerance and objectives. To see which strategies are currently leading the platform, visit the Trending AI Robots page and review the latest performance metrics.
Head-to-Head Comparison
The most fundamental contrast between these two stocks is stage of development. RCKT is a commercial-stage company with an approved gene therapy and a diversified pipeline spanning cardiovascular, hematology, and immunology programs. NKTX is pre-revenue, with its entire value concentrated in the clinical success of NKX019 in autoimmune disease.
On growth drivers, RCKT benefits from multiple late-stage programs and near-term regulatory milestones, including the ongoing Danon disease pivotal trial. NKTX's growth narrative hinges on a single clinical dataset expected in 2026, which creates a more binary risk-reward profile. From a funding perspective, RCKT has diversified its capital sources through non-dilutive proceeds and debt, while NKTX relies on a cash balance that, while runway-extending, may require future equity issuance. Sector exposure also differs: NKTX competes in the crowded cell therapy autoimmune space, whereas RCKT targets orphan cardiovascular and genetic diseases with comparatively fewer direct competitors. On sentiment, RCKT has seen steadier momentum tied to regulatory clarity, while NKTX trades below its cash position, reflecting persistent market skepticism.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor RCKT in the current environment. Rocket Pharmaceuticals demonstrates greater trend consistency, a more stable commercial and regulatory footing, multiple independent catalysts, and a recently strengthened balance sheet. These attributes generally translate into more reliable momentum signals for automated systems than a single-asset, pre-revenue clinical story. NKTX, by contrast, carries higher event-driven risk concentrated in one pivotal dataset, which may appeal to aggressive, catalyst-focused strategies but introduces greater volatility. Accordingly, an AI model weighting stability, diversification, and near-term catalysts would most plausibly assign a higher relative probability of favorable positioning to RCKT, while acknowledging that positive data from NKTX could materially shift the balance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTX is a Hold and RCKT is a StrongBuy.
Momentum Indicator for NKTX turns negative, indicating new downward trend
NKTX saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 74 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NKTX turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
NKTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NKTX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 209 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (2.988). P/E Ratio (-1.101) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCKT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RCKT turned positive on October 20, 2026. Looking at past instances where RCKT's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RCKT's RSI Oscillator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCKT advanced for three days, in 204 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RCKT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for RCKT crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCKT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RCKT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.655) is normal, around the industry mean (2.988). P/E Ratio (-13.750) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RCKT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCKT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NKTX | RCKT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 92 | |
PRICE GROWTH RATING 1..100 | 87 | 85 | |
P/E GROWTH RATING 1..100 | 15 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCKT's Valuation (12) in the Biotechnology industry is in the same range as NKTX (38) in the null industry. This means that RCKT’s stock grew similarly to NKTX’s over the last 12 months.
RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NKTX (100) in the null industry. This means that RCKT’s stock grew similarly to NKTX’s over the last 12 months.
RCKT's SMR Rating (92) in the Biotechnology industry is in the same range as NKTX (97) in the null industry. This means that RCKT’s stock grew similarly to NKTX’s over the last 12 months.
RCKT's Price Growth Rating (85) in the Biotechnology industry is in the same range as NKTX (87) in the null industry. This means that RCKT’s stock grew similarly to NKTX’s over the last 12 months.
RCKT's P/E Growth Rating (14) in the Biotechnology industry is in the same range as NKTX (15) in the null industry. This means that RCKT’s stock grew similarly to NKTX’s over the last 12 months.
| NKTX | RCKT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 4 days ago 89% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 84% |
| Advances ODDS (%) | about 1 month ago 85% | 3 days ago 80% |
| Declines ODDS (%) | 3 days ago 90% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 75% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NKTX’s FA Score shows that 1 FA rating(s) are green while RCKT’s FA Score has 2 green FA rating(s).
- NKTX’s FA Score: 1 green, 4 red.
- RCKT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NKTX’s TA Score shows that 4 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).
- NKTX’s TA Score: 4 bullish, 7 bearish.
- RCKT’s TA Score: 5 bullish, 3 bearish.
Price Growth
NKTX (@Biotechnology) experienced Đ° -13.79% price change this week, while RCKT (@Biotechnology) price change was -0.45% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
NKTX is expected to report earnings on Nov 09, 2026.
RCKT is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | +0.57% | ||
| EDIT - NKTX | 51% Loosely correlated | -2.71% | ||
| CRSP - NKTX | 49% Loosely correlated | +1.24% | ||
| PROK - NKTX | 47% Loosely correlated | N/A | ||
| VIR - NKTX | 47% Loosely correlated | -1.58% | ||
| RCKT - NKTX | 47% Loosely correlated | -5.98% | ||
More | ||||
RCKT and
Correlation & Price change
A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with FDMT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To RCKT | 1D Price Change % | ||
|---|---|---|---|---|
| RCKT | 100% | -5.98% | ||
| FDMT - RCKT | 56% Loosely correlated | -3.66% | ||
| PRME - RCKT | 55% Loosely correlated | -2.81% | ||
| EDIT - RCKT | 55% Loosely correlated | -2.71% | ||
| VYGR - RCKT | 55% Loosely correlated | -7.76% | ||
| STOK - RCKT | 55% Loosely correlated | -3.49% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BINT | 32.12 | 0.16 | +0.50% |
| Bluemonte Global Equity ETF (BINT) | |||
| NLSI | 59.95 | 0.15 | +0.24% |
| NEOS Long/Short Equity Income ETF (NLSI) | |||
| DECZ | 44.07 | N/A | N/A |
| TrueShares Structured Outcome (December) ETF (DECZ) | |||
| ITB | 86.57 | -0.75 | -0.86% |
| iShares U.S. Home Construction ETF (ITB) | |||
| IBUY | 70.53 | -0.87 | -1.22% |
| Amplify Online Retail ETF (IBUY) | |||